Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-06-02 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
第一期员工持股计划实施进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of the company's first employee stock ownership plan, including details about fund raising and implementation status. It references regulatory guidelines and previous meeting approvals but does not contain financial statements or detailed financial data. The document is relatively short (782 characters) and serves as an update on a capital-related activity (employee stock ownership plan). This fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes, specifically employee stock plans.
2016-06-02 Chinese
第八届董事会第五十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the decisions made by the board, including termination of a private stock issuance, approval of related party transactions, and the calling of a shareholders' meeting. The document includes voting results and references to other announcements for further details. It does not contain financial statements, audit information, or detailed management discussion. It is not a report itself but an announcement of board meeting resolutions. Therefore, it fits best under 'Board/Management Information' (MANG). The document length is short and focused on board decisions, confirming this classification with high confidence.
2016-06-02 Chinese
关于湖州融源瑞康股权投资合伙企业（有限合伙）合伙份额转让、天津开发区德源投资发展有限公司、永泰红磡控股集团有限公司为公司提供反担保暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving the transfer of partnership shares and provision of counter-guarantees among related companies. It includes specifics about the parties involved, the terms of the agreements, and the approval process by the board and shareholders. There is no indication that this is a financial report, earnings release, or regulatory certification. The content focuses on a corporate transaction and related guarantees, which fits the category of Capital/Financing Update (CAP) as it relates to changes in capital structure and financing arrangements. The document length is sufficient and contains substantive details, not just an announcement of a report or a certification. Therefore, the appropriate classification is CAP with high confidence.
2016-06-02 Chinese
独立董事关于第八届董事会第五十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 52nd meeting of the 8th board of directors of the company. It discusses the termination of a non-public stock issuance and related guarantee and related-party transactions. The document is a formal opinion related to board decisions and governance matters, not a full financial report or earnings release. It is not a report publication announcement or certification. The content aligns with Board/Management Information (MANG) as it relates to board decisions and governance matters.
2016-06-02 Chinese
关于终止非公开发行股票事项召开投资者说明会预告暨公司股票继续停牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the scheduling of an investor briefing meeting about the termination of a non-public stock issuance. It includes details about the meeting time, location, participants, and how investors can attend and interact. The document also mentions the continuation of stock suspension pending the meeting and subsequent disclosure. The content is focused on informing investors about the meeting and related procedural updates rather than presenting financial data, earnings, or detailed reports. The document length is short (1332 characters), and it serves as a notice or announcement rather than a full report or transcript. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to financing activities (termination of a non-public stock issuance) and investor communication about that matter.
2016-06-02 Chinese
关于对上海证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 中源协和细胞基因工程股份有限公司 responding to regulatory inquiry letters from the Shanghai Stock Exchange regarding the impact of the "魏则西" incident on the company's business, specifically its non-public stock issuance and acquisition plans. It includes detailed disclosures about the company's business strategy, financial data related to immune cell therapy projects, risk factors, and responses to regulatory questions. The document is lengthy (7410 characters) and contains substantive financial and operational information, not merely an announcement of a report or a certification. It is not a full annual or interim report but rather a regulatory response with detailed disclosures about business risks, financing termination, and operational impacts. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement responding to inquiries and disclosing material information but does not constitute a full financial report like an Annual Report or Interim Report.
2016-06-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.